Navigation Links
DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs
Date:5/5/2011

nt class-wide REMS announcement for extended release opioids.  Pfizer stated that these issues could delay the timing of approval or the launch of REMOXY.  As a result of its acquisition of King, Pfizer has assumed the development and commercialization rights and obligations to REMOXY.  

REMOXY, an investigational drug, is a unique long acting oral formulation of oxycodone intended to treat moderate to severe pain. Based on DURECT's ORADUR® technology, which is covered by issued patents and pending patent applications owned by us, REMOXY is designed to resist common methods of prescription drug misuse and abuse.   An abuse liability study was recently published in Pain Medicine, the Official Journal of the American Academy of Pain Medicine.  In this study of REMOXY versus Oxycodone ER tested in volunteers with a history of opioid abuse, REMOXY met all prospectively defined primary endpoints.  See "The Abuse Potential of Remoxy®, an Extended-Release Formulation of Oxycodone, Compared with Immediate- and Extended-Release Oxycodone" (Pain Medicine 2011; 12; 618-631).  This study complements previously published data on the extraction under various conditions of oxycodone from REMOXY; see "Remoxy®: A Novel Formulation of Extended-Release Oxycodone Developed Using the ORADUR® Technology" (The Journal of Applied Research, Vol.10, No.3, 2010)  which is accessible on DURECT's website at www.durect.com/wt/durect/page_name/Publications.

  • POSIDUR (SABER™-Bupivacaine) Post-Operative Pain Relief Depot. During the first quarter of 2011, we continued enrolling patients in our U.S. pivotal Phase III clinical study known as BESST (Bupivacaine Effectiveness and Safety in SABER Trial).  We expect to complete enrollment of BESST, comprising approximat
    '/>"/>

    • SOURCE DURECT Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. DURECT Corporation Announces Fourth Quarter and Year End 2010 Financial Results
    2. DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call
    3. DURECT Corporation Announces Third Quarter 2008 Financial Results
    4. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
    5. Techne Corporation Declares Dividend
    6. Techne Corporation Announces Acquisition
    7. SynapDx Corporation Licenses Autism Diagnostic Discoveries From Childrens Hospital Boston
    8. Vestaron Corporation Announces New Leadership
    9. Mitsubishi Chemical Corporation Signs Memorandum of Understanding for Strategic Partnership With Genomatica for Sustainable Chemicals in Asia
    10. Every Day is Earth Day for Yulex Corporation
    11. Veteran Wall Street Securities Analyst Reports on Health Discovery Corporation
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/17/2013)... -- New interactive learning forums will ... of the medical device industry at the 2013 ... from June 18-20 in Philadelphia ... ) , These all-new MedTech Innovate ... presentations and implementable solutions on the most cutting-edge ...
    (Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- Aridis is pleased to announce ... Switzerland -based Kenta Biotech to acquire ... (mAb) products, and technologies. This asset portfolio purchase ... of infections by common pathogens including drug resistant ... Pseudomonas aeruginosa , Acinetobacter baumannii and ...
    (Date:5/17/2013)... 17, 2013 The paradigm of ‘one ... systems that can help predict the adverse and therapeutic ... Stepaniants, Head of Computational Biology at the Genomics Laboratory, ... to ensure high-quality genomics when used as part of ... to complex data sets to identify key clinical targets ...
    (Date:5/17/2013)... Brea, CA (PRWEB) May 17, 2013 IAC ... DisperSol Technologies, a start up laboratory needing to set up ... be moving to a larger facility within a year’s time. ... the knowledge that the laboratory is temporary? What is efficient ... 4 Series modular workstations from IAC Industries. The planners at ...
    Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
    ... CellCyte Genetics,Corporation (the "Company") (OTC Bulletin Board: CCYG) ... develop, manufacture and market its patented,line of stem ... is developing stem cell enabling therapeutic products,designed to ... adult stem cells to diseased organs, such as ...
    ... Expand Versatility of DelSite cGMP Polymer, ... (Pink Sheets: CARN) today announced its wholly-owned,subsidiary, ... rights license agreement with a biotechnology company ... DelSite,s,high-molecular-weight anionic polysaccharide which is produced under ...
    ... Sept. 19 /Xinhua-PRNewswire/ -- Shanghai Century (Amex:,SHA), a ... Pharmaceutical Co., Ltd (Kelun), China,s largest producer of,intravenous ... financial highlights with respect to the consolidated results ... interest entity,(Kelun Group) for the first half of ...
    Cached Biology Technology:CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products 2CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products 3CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products 4Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines 2Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 2Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 4Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 5
    (Date:5/16/2013)... MA -- Injectable nanoparticles developed at MIT may ... 1 diabetes to constantly monitor their blood-sugar levels ... were designed to sense glucose levels in the ... of insulin, thereby replacing the function of pancreatic ... Type 1 diabetes. Ultimately, this type of system ...
    (Date:5/16/2013)... an ancient extinct creature with ,scissor hand-like, claws in ... his favourite movie star. , The 505 million ... Koo-ten-ee-che-la depp-eye), which is a distant ancestor of lobsters ... for his starring role as Edward Scissorhands - a ... creation, who has scissors for hands. , ...
    (Date:5/16/2013)... Cameroon and the manager of San Diego Zoo Global,s ... Whitley award. The Whitley award is an international ... it celebrates the extraordinary achievements of some of the ... was selected for the award due to his efforts ... its wildlife inhabitants., HRH The Princess Royal, the charity,s ...
    Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3Actor Johnny Depp immortalized in ancient fossil find 2Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3
    ... and WEST PALM BEACH, Fla. , May ... authentication and endpoint protection solutions and ScriptRx, a leading ... Systems for Emergency Rooms and Urgent Care Centers, today ... into the ScriptRx System. Designed for these busy clinical ...
    ... A research appearing in Nature , with ... from the Department of Genetics and Microbiology at UAB, ... virulent genes causing infections. The research describes an unprecedented ... of treating and preventing bacterial infections. , Pathogenic ...
    ... transport through shipping, income from tourism and recreation ... is a challenge that calls for reframing humans as ... of Europe,s leading marine organisations in a new report ... Board-European Science Foundation (ESF), the International Council for the ...
    Cached Biology News:ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 2ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 3ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 4Surprising infection inducing mechanism found in bacteria 2Sustainable use of our seas needs an integrated view of humans and nature 2
    ... peptide derived from the internal region of ... Specific for the internal region of the ... the target band at ~590 kDa. ... media from primary tracheobranchial epithelial cultures and ...
    ...
    Request Info...
    Penicillin-Streptomycin liquid...
    Biology Products: